Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Sarepta Therapeutics (NASDAQ:SRPT) has announced the sale of about 9.3M shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in ...

Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock dropped 6% after Sarepta Therapeutics (NASDAQ:SRPT) announced it sold over 9.2 million shares of Arrowhead in a privately negotiated ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO Capital adjusted its price target for Sarepta to $25 from $50, while ...

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

News GlobeNewswire SRPT INVESTORS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investors may have been Affected by Fraud – Contact BFA Law by August 25 about Potentially Recovering Losses ...